title: Can the nephron be spared?
abstract: The search continues for the best role for mTOR inhibitor drugs in renal transplantation-principally to avoid or minimize the nephrotoxicity of the CNI class of immunosuppressive agents. The Spare the Nephron Trial describes the popular approach of early conversion from a CNI to the mTOR agent sirolimus for patients maintained on mycophenolate mofetil and steroids. At 1-2 years the glomerular filtration rate (GFR) was superior for the sirolimus group, with a loss of tolerability for about 20%.
authors: Cleveland Clinic Lerner College of Medicine, Glickman Urological and Kidney Institute, Cleveland, Ohio 44195, USA. flechns@ccf.org
authors: Stuart M
authors: SM
authors: Flechner
mesh_terms: D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000502:physiology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D009399:Nephrons / Q000187:drug effects* / Q000502:physiology; D020123:Sirolimus / Q000009:adverse effects; D013256:Steroids / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D013256:Steroids; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D009173:Mycophenolic Acid; D020123:Sirolimus